Decrease of glutathione peroxidase in arrhythmic cardiac pathology in young individuals and its therapeutic implications.

Autor: Bezna MC; Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Pisoschi C; Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Bezna M; Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Danoiu S; Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Tudorascu IR; Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Negroiu CE; Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania., Melinte PR; Department of Human Anatomy, University of Medicine and Pharmacy of Craiova, Emergency Hospital, 200330 Craiova, Romania.
Jazyk: angličtina
Zdroj: Biomedical reports [Biomed Rep] 2022 Oct 07; Vol. 17 (6), pp. 93. Date of Electronic Publication: 2022 Oct 07 (Print Publication: 2022).
DOI: 10.3892/br.2022.1576
Abstrakt: Glutathione peroxidase (GPx), as an antioxidant enzyme, is involved in the regulation of processes that cause cellular oxidative stress, with implications in various pathologies. The aim of the present study was to evaluate GPx variations in patients with arrhythmic, non-structural cardiac disorders. The research was performed on 120 patients, with a mean age of 33 years old, divided into 3 equal groups, of which 2 groups included patients with cardiac arrhythmias, the first group, associated with dyslipidemia and the second one, without dyslipidemia, and a control group consisting of healthy individuals. The method for determining GPx was based on the GPx enzyme catalysis reaction of the reduced glutathione (GSH) oxidation reaction by cumene hydroperoxide. The results revealed that GPx variation was decreased in patients with cardiac arrhythmias, with or without dyslipidemia, up to 66 and 74% of mean control values, respectively, the differences being statistically significant, showing the existence of an oxidative stress imbalance, that may be involved in triggering arrhythmogenic electrochemical mechanisms. The GPx deficiency determined in relation to cardiac arrhythmias was in dyslipidemic and non-lipidemic patients as follows: 29-35% in sinus bradycardia, 31-35% in associated cardiac arrhythmias, 30-33% in sinus tachycardia, 27-33% in atrial fibrillation, 32-33% in atrial flutter, 27-32% in atrial extrasystolic arrhythmia, 28-30% in ventricular extrasystolic arrhythmia and 18-26% in paroxysmal supraventricular tachycardia. Collectively, the results revealed that GPx, an antioxidant enzyme, is a specific biomarker, whose decrease indicated the existence of oxidative stress in young individuals with cardiac arrhythmias and its involvement in arrhythmogenic electrochemical processes. In addition, GPx deficiencies were between 18-35% in all types of cardiac arrhythmias, the highest being recorded in sinus bradycardia and the lowest in paroxysmal supraventircular tachycardia. Furthermore, the oxidative stress favored by the decrease of GPx induced lipid oxidation, regardless of the presence or absence of dyslipidemia, which triggered the formation of anti-lipid antibodies and a subclinical endothelial aggression, with early atherosclerotic potential. GPx evaluation may argue for the existence of oxidative stress in non-structural cardiac arrhythmias, and by its proper correction (antioxidants), prophylaxis of atherogenic dysfunction.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © Bezna et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje